Search
Adenosine
go.drugbank.com/drugs/DB00640ApprovedInvestigationalThe structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though i...
Mixtures: BOTA C Reset, The Prestige BB SPF25 PA 2PlusCategories: Purinergic P1 Receptor AgonistsPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsCathine
go.drugbank.com/drugs/DB01486ExperimentalIllicitIt belongs to the phenethylamine and amphetamine chemical classes. In the United States, it is classified as a Schedule IV controlled substance.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsTacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparatio...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsProducts: Envarsus PaSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalSerplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for ...
Mixtures: Dex-Moxi PF, DexMoxiKetor PFCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMonopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Mixtures: Isolyte S pH 7.4, ISOLYTE-S PH 7.4 PVC 500 ML(SETLI)Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … Dostarlimab is an IgG<sub>4</sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsTenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors